A nurse is handed a dose of the Pfizer Covid-19 vaccine before administering it to a college student during a mobile vaccination clinic at the California State University, Long Beach, on Aug. 11.
The Food and Drug Administration has formally approved Pfizer’s COVID-19 vaccine. The widely anticipated decision replaces the emergency use authorization granted by the agency last December.
This is the first COVID-19 vaccine to be subject to a full review by the U.S. regulator and to get an approval that puts the vaccine on par with other marketed vaccines.
The full approval could make it easier for employers, the military and universities to mandate vaccination and may reassure some people hesitant about the vaccine.
A June poll from the Kaiser Family Foundation found that 31% of unvaccinated people said they would be more likely to get a COVID-19 vaccine once one receives full approval from the FDA.
“While millions of people have already safely received COVID-19 vaccines, we recognize that for some, the FDA approval of a vaccine may now instill additional confidence to get vaccinated,” acting FDA Commissioner Janet Woodcock said in a statement. “Today’s milestone puts us one step closer to altering the course of this pandemic in the U.S.”
The FDA acted Monday without convening a customary public meeting of expert advisers to vet information about the vaccine and make recommendations to the regulator.
As of Sunday, 73% of adults have had at least one dose of the Pfizer, Moderna or Johnson & Johnson vaccine. Pfizer’s vaccine is most commonly administered, accounting for about 56% of the doses administered overall, according to data from the Centers for Disease Control and Prevention.
Moderna’s COVID-19 vaccine remains under FDA’s review, but its approval is expected to follow in the near future.